申请人:Topivert Pharma Limited
公开号:US20140296208A1
公开(公告)日:2014-10-02
There are provided compounds of formula I,
wherein R
1A
to R
1E
, R
2
to R
5
, L and X
1
to X
3
have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
提供了具有式I的化合物,
其中R
1A至R
1E,R
2至R
5,L和X
1至X
3在描述中给出了含义,这些化合物具有抗炎活性(例如通过抑制p38丝裂原活化蛋白激酶酶家族中的一个或多个成员;Syk激酶;和酪氨酸激酶Src家族的成员之一)并且在治疗中有用,包括在药物组合中,特别是在治疗炎症性疾病,包括肺部、眼睛和肠道的炎症性疾病。